What do systematic reviews say?

Azithromycin vs cefaclor

It is very uncertain whether azithromycin changes clinical cure (measured 7 days after treatment) compared with cefaclor (very low certainty).

• Interventions for bacterial folliculitis and boils (furuncles and carbuncles) 2021 · Cochrane Headline outcomes only
  RR 1.01 [0.72, 1.4]
  2 studies · 31 participants
  Very low

Azithromycin vs cefaclor

• Interventions for bacterial folliculitis and boils (furuncles and carbuncles) 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2744 participants
  Very low

Azithromycin vs cefaclor

It is very uncertain whether azithromycin changes minor adverse events not leading to withdrawal of treatment… compared with cefaclor (very low certainty).

• Interventions for bacterial folliculitis and boils (furuncles and carbuncles) 2021 · Cochrane Headline outcomes only
  RR 1.26 [0.38, 4.17]
  2 studies · 2744 participants
  Very low

Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d

Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).

• Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
  RR 0.51 [0.34, 0.76]
  2 studies · 93 participants
  Moderate

Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d

• Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Moderate

Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d

The review found no eligible studies for this question.

• Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found